Compare TARS & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TARS | VCEL |
|---|---|---|
| Founded | 2016 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.4B |
| IPO Year | 2020 | 1996 |
| Metric | TARS | VCEL |
|---|---|---|
| Price | $78.18 | $39.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $89.00 | $57.75 |
| AVG Volume (30 Days) | ★ 705.3K | 439.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 48.21 | ★ 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $451,360,000.00 | $276,259,000.00 |
| Revenue This Year | $56.43 | $19.40 |
| Revenue Next Year | $30.19 | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 146.71 | 16.45 |
| 52 Week Low | $48.79 | $28.95 |
| 52 Week High | $91.53 | $49.32 |
| Indicator | TARS | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 58.64 | 40.84 |
| Support Level | $77.14 | $35.45 |
| Resistance Level | $84.66 | $41.25 |
| Average True Range (ATR) | 3.77 | 1.17 |
| MACD | -0.04 | -0.17 |
| Stochastic Oscillator | 47.52 | 40.51 |
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.